substantial proportion of 2016 Medicare Part D spending was for drugs with absent or low-quality cost-effectiveness analyses ?
Is this a LAST PUSH for the generic industry to cement their place on formularies of PBM and “nose out” brand name meds ? About 10%-12% of all meds provide the funding for new med Resea…
